This publication summarises presentations given Btk inhibition in CLL at the Chronic Lymphocytic Leukaemia Australian Research Consortium (CLL ARC) Forum held in Sydney, Australia on 23rd and 24th September 2016.
The forum was chaired by Professor Stephen Mulligan, University of Sydney, Australia and the programme included keynote presentations from Professor Michael Keating of the MD Anderson Center, USA and Professor Arnon Kater, University of Amsterdam, Netherlands, alongside presentations by leading Australian clinical and translational researchers in the field of CLL.
Please login below to download this issue (PDF)